Last update 08 May 2025

Santen Pharmaceutical Korea Co., Ltd.

Subsidiary Company|2000|Seoul, South Korea|
www.santen.co.kr

Overview

Tags

Eye Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
no Data
No Data
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
Small molecule drug2
Top 5 TargetCount
EP2(Prostanoid EP2 receptor)1
ROCK(Rho-associated kinases)1

Related

2
Drugs associated with Santen Pharmaceutical Korea Co., Ltd.
Omidenepag Isopropyl
Target
EP2
Mechanism
EP2 agonists
Active Org.
Santen Pharmaceutical Co., Ltd.Santen Pharmaceutical Co., Ltd. [+2]
Originator Org.
UBE Corp.UBE Corp.
Active Indication
Glaucoma [+2]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
Japan
First Approval Date21 Sep 2018
Netarsudil Mesylate
Target
ROCK
Mechanism
ROCK inhibitors
Active Org.
Santen Pharmaceutical Korea Co., Ltd. [+2]
Originator Org.
Aerie Pharmaceuticals, Inc.Aerie Pharmaceuticals, Inc.
Active Indication
Glaucoma, Open-Angle [+1]
Inactive Indication
Corneal Edema [+2]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date18 Dec 2017
100 Clinical Results associated with Santen Pharmaceutical Korea Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Santen Pharmaceutical Korea Co., Ltd.
Login to view more data
100 Deals associated with Santen Pharmaceutical Korea Co., Ltd.
Login to view more data
100 Translational Medicine associated with Santen Pharmaceutical Korea Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 Oct 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
2
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Omidenepag Isopropyl
 ( EP2 )		Ocular Hypertension
More
Approved
Netarsudil Mesylate
 ( ROCK )		Glaucoma, Open-Angle
More
Approved
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free